The transition for the Nasdaq-listed firm occurs after the close of U.S. markets on Friday, June 26. FTSE Russell determines membership through objective, market-capitalization rankings and style attributes, capturing data as of April 30, 2026. Inclusion in the Russell 3000 Index provides a gateway for companies to be categorized into large-cap or small-cap benchmarks, influencing how institutional investors allocate capital across their portfolios.

Investment managers rely heavily on these indexes to track performance and manage index-based funds. With approximately $12.2 trillion in assets currently benchmarked against the Russell U.S. indexes, the addition marks a shift in Oramed’s market standing within the broader investment landscape.